8月20日 - ** 远程医疗公司 Hims & Hers Health（HIMS.N）的股价在早盘交易中上涨 4%，至 32.35 美元
** 巴克莱表示，预计HIMS的营收将实现增长，这主要得益于收购以及新业务领域的强劲增长
** 但该行认为，“为支持增长而进行的投资将带来一定利润率压力”，这可能对近期盈利能力构成拖累
** 该券商将该股目标价从39美元下调至35美元；维持“增持”评级
** 新目标价较该股上一交易日收盘价仍有12%的上行空间
** 本月初，HIMS在积极推进品牌GLP-1减肥药及国际扩张导致成本上升的情况下，第二季度营收仍超出 (link) 预期
** 16家券商中有4家给予该股“买入”或更高评级，12家给予“持有”评级；其目标价中位数为30.5美元——数据由LSEG汇编
** 截至上一交易日收盘，该股今年以来累计下跌4.3%
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.